Amiodarone-induced liver injury with bright liver sign: A case report

Figure 2 Serial liver imaging before and after amiodarone therapy. A and B: Chest computed tomography (CT) performed before initiation of amiodarone therapy (January 16, 2025) demonstrates homogeneous hepatic attenuation [approximately 52 Hounsfield units (HU)], comparable to that of the spleen; C and D: Chest CT obtained after amiodarone therapy (June 3, 2025) reveals a marked increase in hepatic attenuation (approximately 120 HU), substantially exceeding splenic attenuation. The liver is normal in size and contour, with smooth margins and no focal lesions; E-I: Abdominal magnetic resonance imaging performed after amiodarone therapy (June 5, 2025) demonstrates isointense hepatic parenchymal signal on T1-weighted imaging and mildly hypointense signal on T2-weighted imaging. No appreciable signal loss is observed on in-phase or out-of-phase sequences.